PMA 101RAlternative Names: PMA-101R
Latest Information Update: 18 Jul 2016
At a glance
- Originator Pharmedartis
- Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Atopic dermatitis; Inflammation; Psoriasis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 18 Jul 2016 PMA 101R is still in preclinical development for Acute myeloid leukaemia, Solid tumours, Inflammation, Rheumatoid arthritis, Atopic dermatitis and Psoriasis in Germany